Public Profile

Dr. Falk Pharma GmbH

Dr. Falk Pharma GmbH, headquartered in Germany, is a prominent player in the pharmaceutical industry, specialising in the development and marketing of innovative therapies for gastrointestinal and liver diseases. Founded in 1960, the company has established a strong presence across Europe and beyond, focusing on areas such as inflammatory bowel disease and hepatology. With a commitment to research and development, Dr. Falk Pharma offers a range of unique products and services that address unmet medical needs. Their portfolio includes prescription medications and specialised nutritional products, distinguished by their efficacy and safety profiles. Recognised for its dedication to patient care, Dr. Falk Pharma has achieved significant milestones, solidifying its position as a trusted partner in the healthcare community.

DitchCarbon Score

How does Dr. Falk Pharma GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

10

Industry Average

Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

14

Industry Benchmark

Dr. Falk Pharma GmbH's score of 10 is lower than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.

11%

Let us know if this data was useful to you

Dr. Falk Pharma GmbH's reported carbon emissions

Dr. Falk Pharma GmbH, headquartered in Germany, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures or defined climate commitments, it is unclear how the company is addressing its carbon footprint. In the pharmaceutical industry, companies are increasingly focusing on sustainability and climate action, often setting science-based targets to reduce emissions across Scope 1, 2, and 3. However, as of now, Dr. Falk Pharma GmbH has not disclosed any such initiatives or commitments.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Dr. Falk Pharma GmbH's primary industry is Chemicals nec, which is medium in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Dr. Falk Pharma GmbH is in DE, which has a medium grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Dr. Falk Pharma GmbH is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Takeda

JP
Medical, precision and optical instruments, watches and clocks (33)
Updated 4 days ago

Ferring Pharmaceuticals Inc.

US
Chemicals nec
Updated 3 months ago
DitchCarbon Score

Regeneron

US
Research and development services (73)
Updated 2 days ago

Faes Farma

ES
Medical, precision and optical instruments, watches and clocks (33)
Updated 4 days ago

Bausch Health Cos

CA
Medical, precision and optical instruments, watches and clocks (33)
Updated 4 days ago

Tillotts Pharma AG

CH
Chemicals nec
Updated about 1 month ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers